6CM
ARMP icon

683 Capital Management’s Armata Pharmaceuticals ARMP Stock Holding History

683 Capital Management’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-137,000
Closed -$1.4M – 162
2026
Q1 		$1.4M Sell
137,000
-2,860
-2% -$24.1K 0.07% 127
2025
Q4 		$878K Buy
+139,860
New +$766K 0.04% 153

Other funds holding ARMP

MAM
Madison Asset Management Madison, Wisconsin $8.39B AUM 16.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

683 Capital Management's ARMP Position: Q2 2026 in Review

683 Capital Management sold out of Armata Pharmaceuticals (ARMP) in Q2 2026, closing a stake of 137,000 shares — an estimated $1.4M sold.

683 Capital Management first reported a position in ARMP in Q4 2025 and held it in 2 quarters. The position peaked at $1.4M in Q1 2026. 53 funds tracked by Wall St. Rank hold ARMP as of Q2 2026.

  • 683 Capital Management reported no remaining Armata Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 137,000 Armata Pharmaceuticals shares in Q2 2026, an estimated $1.4M.
  • 683 Capital Management first reported a position in Armata Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • 683 Capital Management's Armata Pharmaceuticals position peaked at $1.4M in Q1 2026.
  • 53 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.